Compare VRTS & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VRTS | MPLT |
|---|---|---|
| Founded | 1988 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 992.3M | 811.3M |
| IPO Year | 1995 | N/A |
| Metric | VRTS | MPLT |
|---|---|---|
| Price | $126.38 | $19.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $171.60 | $31.00 |
| AVG Volume (30 Days) | 62.3K | ★ 126.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.52% | N/A |
| EPS Growth | ★ 18.24 | N/A |
| EPS | ★ 19.97 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.84 | N/A |
| P/E Ratio | $6.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $127.67 | $12.24 |
| 52 Week High | $214.88 | $21.55 |
| Indicator | VRTS | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 28.97 | 59.78 |
| Support Level | N/A | $16.17 |
| Resistance Level | $169.44 | $20.20 |
| Average True Range (ATR) | 4.70 | 1.18 |
| MACD | -0.56 | 0.15 |
| Stochastic Oscillator | 2.53 | 70.90 |
Virtus Investment Partners Inc provides investment management and related services to institutions and individuals. It uses a multi-manager, multi-style approach, offering investment strategies from investment managers, each having its distinct investment style, autonomous investment process, and individual brand, as well as from select unaffiliated managers for certain funds. Through its multi-manager model, the group provides investment managers with distribution, business, and operational support. The Company operates in one business segment, namely as an asset manager providing investment management and related services for individual and institutional clients.
MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.